Skip to content

Author

N. R. Prasad

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Tryptoline urea derivatives for sensitizing resistant breast cancer cells to doxorubicin.

Co-administration of compound 9 with doxorubicin (DOX) significantly reduced fold resistance in MCF-7/DXR cells, almost restoring their sensitivity to levels similar to the parental cell line, and compound 9 acted synergistically with DOX, markedly increasing its cytotoxicity, associated with a strong increase in apopt...

Filipa Barbosa, Karankumar Balamurugan, N. R. Prasad et al. · 0 citations
Sep 2026

Ebselen sensitizes multidrug-resistant cancer cells to doxorubicin by disrupting cellular redox homeostasis and inducing ferroptosis.

AIM Multidrug resistance (MDR), driven by P-glycoprotein (P-gp/ABCB1)-mediated drug efflux and enhanced antioxidant defenses, remains a major obstacle to effective chemotherapy. This study investigated whether thioredoxin reductase (TrxR) inhibition by ebselen induces ferroptosis, suppresses NRF2/Keap1 signaling and re...

S. Baskar, S. Anbiah, N. R. Prasad · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.